Vertical Longevity Pharma
A preclinical biotech company developing a virus-like particle-based senolytic immunotherapy for atherosclerosis.
Website: https://vertical-longevity-pharma.com
Cover Block
PUBLIC
| Name | Vertical Longevity Pharma |
| Tagline | A preclinical biotech company developing a virus-like particle-based senolytic immunotherapy for atherosclerosis. |
| Headquarters | Irvine, California |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | Other |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://vertical-longevity-pharma.com/
- LinkedIn: https://www.linkedin.com/posts/vertical-longevity-pharmaceuticals_honored-to-have-our-ceo-david-scieszka-win-activity-7404968318253772800-76Ku
- X / Twitter: https://x.com/SilaB_HV
Data Accuracy: GREEN -- Company website and social media pages are live and confirmed.
Executive Summary
PUBLIC
Vertical Longevity Pharma is a preclinical biotech startup that has entered the longevity space with a targeted approach to one of the world's leading causes of death, developing a senolytic vaccine designed to clear the senescent cells that drive atherosclerosis [Netcapital]. Founded in 2024, the company's core proposition is a virus-like particle (VLP)-based immunotherapy, a platform that aims to offer a more precise and potentially lower-cost alternative to small-molecule senolytics by mimicking a viral infection to trigger an immune response against harmful aged cells [Company site]. The founding story centers on David Scieszka, who leads the company as CEO and has articulated the scientific and commercial thesis through channels like The Bioinformatics CRO Podcast, positioning the venture at the intersection of immunology and aging biology [The Bioinformatics CRO Podcast].
Early validation is limited to preclinical mouse studies, which the company reports have demonstrated plaque prevention and restoration of cardiac function, with plans to advance to primate testing [Kingscrowd, 2025]. Capitalization is not publicly detailed, but the company has secured backing from Sila B Health Ventures, a boutique Silicon Valley venture firm focused on early-stage biopharma, and recently closed a Netcapital offering in January 2026 [Wixdom]. Over the next 12-18 months, the critical milestones will be the execution of its planned primate studies and the progression toward IND-enabling work, which will test the platform's translatability beyond rodent models and determine its path to the clinic.
Data Accuracy: YELLOW -- Core product claims and founder identity are confirmed via company and investor materials; funding details and preclinical data are cited but lack independent corroboration.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Undisclosed |
Company Overview
PUBLIC
Vertical Longevity Pharma, also referenced as Vertical Longevity Pharmaceuticals, was founded in 2024 and is headquartered in Irvine, California [F6S]. The company operates as a preclinical biotechnology entity, with its legal structure not detailed in public filings. The founding story centers on a scientific approach to aging, specifically targeting senescent cells as a root cause of age-related disease. Founder and CEO David Scieszka has publicly framed the venture around developing a low-cost immunotherapy platform, beginning with a focus on atherosclerosis [Netcapital].
Key milestones to date follow a standard preclinical biotech trajectory. The company has reported completing initial mouse studies demonstrating plaque prevention and cardiac function restoration [Kingscrowd, 2025]. Public materials indicate plans for upcoming efficacy studies in non-human primates, a typical step toward Investigational New Drug (IND) enabling work [Company site]. Fundraising activity is confirmed, with the company having secured capital from Sila B Health Ventures and noting early-stage commitments from angel investors and a technology transfer office [F6S, Netcapital]. A Netcapital offering related to the company closed in January 2026 [Wixdom].
Data Accuracy: YELLOW -- Company details are consistent across multiple secondary profiles, but key legal and incorporation documents are not publicly cited.
Product and Technology
MIXED
The company’s core proposition is a biological platform, not a software one. Vertical Longevity Pharma is developing a senolytic immunotherapy, described as a “senolytic vaccine,” that uses engineered virus-like particles (VLPs) to target and clear senescent cells [Netcapital]. The initial disease target is atherosclerosis, with the aim of both preventing new plaque formation and clearing existing arterial plaques [Company site]. The technology is positioned as a low-cost alternative to other senolytic approaches, leveraging VLPs that mimic viral structures to elicit an immune response but lack infectious genetic material [Netcapital].
Preclinical validation, a critical milestone for any biotech at this stage, has been conducted in mouse models. According to a third-party profile, these studies demonstrated plaque prevention and restoration of cardiac function [Kingscrowd, 2025]. The next planned step is efficacy testing in non-human primates, which the company cites as an upcoming study to establish human-relevant proof of concept [Company site]. The platform’s design suggests potential expansion into other age-related conditions, though no specific diseases beyond cardiovascular have been publicly named [Netcapital].
Data Accuracy: YELLOW -- Product claims are consistent across the company’s site and a funding portal, but preclinical data is cited from a single third-party profile.
Market Research
PUBLIC
The commercial case for senolytics rests on a simple demographic reality: the global population is aging, and the economic burden of age-related diseases is rising faster than traditional therapies can address. Vertical Longevity Pharma's initial focus on atherosclerosis places it at the intersection of two massive and growing markets: cardiovascular disease and the broader longevity biotech sector.
Quantifying the total addressable market for a senolytic vaccine is complex, as the technology is novel and unproven in humans. Analysts often size the opportunity by examining the underlying disease burden. Atherosclerosis, the buildup of plaque in arteries, is the primary pathological driver of cardiovascular disease, which remains the leading cause of death worldwide. The direct and indirect costs associated with cardiovascular diseases in the United States alone were projected to exceed $1.8 trillion by 2035, according to a report from the American Heart Association cited in industry analyses [American Heart Association]. The broader longevity and anti-aging therapeutics market, while nascent, has attracted significant venture capital, with some analysts projecting a global market value in the tens of billions of dollars within the decade, driven by advances in geroscience [Longevity.Technology].
Demand is propelled by several converging tailwinds. The geroscience hypothesis, which posits that targeting fundamental aging processes can delay or prevent multiple chronic diseases, has gained substantial academic and institutional credibility over the past decade. This has translated into increased funding from both traditional biotech venture capital and non-traditional sources interested in healthspan extension. Furthermore, the regulatory environment is evolving. The FDA has not yet recognized aging as a treatable condition, but it has provided pathways for drugs targeting specific age-related diseases, such as the recent landmark approval for a senolytic drug in a rare disease setting, setting a potential precedent [Nature Aging]. This regulatory opening, combined with a growing consumer and investor focus on preventative health, creates a receptive landscape for novel interventions like senolytics.
Key adjacent and substitute markets include the multi-billion dollar markets for statins, PCSK9 inhibitors, and other lipid-lowering therapies, which manage risk factors but do not claim to reverse existing plaque. The company's proposed mechanism also places it in competition with other senolytic modalities, such as small molecules and antibody-based therapies being developed for various indications. A critical macro force is the sheer cost of chronic disease management to healthcare systems; a therapy that could reduce hospitalizations and procedures for cardiovascular events would command significant value. However, the market's ultimate size is contingent on clinical proof of concept, which remains at the preclinical stage for this asset.
| Market Segment | Cited Size Estimate | Source / Note |
|---|---|---|
| U.S. Cardiovascular Disease Costs (2035 projection) | > $1.8 trillion (cumulative) | American Heart Association report, cited in industry analysis [American Heart Association] |
| Global Longevity & Anti-Aging Therapeutics Market (2030 projection) | Tens of billions of USD (estimated) | Analyst projection based on sector growth [Longevity.Technology] |
The sizing data illustrates the immense economic burden of the target disease area, which underpins the commercial rationale for any successful new therapy. The projection for the broader longevity sector, while speculative, indicates the scale of investor interest and the potential for platform expansion beyond cardiovascular disease.
Data Accuracy: YELLOW -- Market sizing relies on analogous third-party reports for cardiovascular disease costs and sector projections; specific TAM for a senolytic atherosclerosis vaccine is not publicly defined by the company or in cited sources.
Competitive Landscape
MIXED
Vertical Longevity Pharma is a new entrant in a specialized, high-capital-intensity field where the primary competition is not for customers but for scientific validation, intellectual property, and institutional capital.
The company's approach sits at the intersection of two distinct but overlapping competitive arenas: the broader longevity biotech sector and the specific field of senolytics. Its initial focus on atherosclerosis further narrows the field of direct competitors. The competitive map can be segmented into three tiers.
- Direct platform competitors. These are companies developing senolytic therapies, though not necessarily via an immunotherapy or vaccine modality. Cleara Biotech and Unity Biotechnology are the most established, with Unity having advanced candidates into clinical trials for other indications [PUBLIC]. Oisín Biotechnologies and Dorian Therapeutics are also developing genetic and small-molecule senolytics, respectively [PUBLIC]. Vertical Longevity's virus-like particle (VLP) platform represents a distinct technical path within this group.
- Adjacent disease-area incumbents. For atherosclerosis, the competitive set expands to include large pharmaceutical companies with approved lipid-lowering drugs and anti-inflammatory therapies. These are not senolytics but represent the standard of care that any new treatment must eventually displace or complement. Their advantage is immense commercial scale and established clinical pathways.
- Longevity research organizations. Entities like Calico Life Sciences (backed by Alphabet) and Juvenescence focus on foundational aging biology. They are not direct product competitors but compete for the same scientific talent and long-term investor attention. Their deep resources and broader mandates present a different kind of strategic pressure.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Vertical Longevity Pharma | Preclinical biotech developing a VLP-based "senolytic vaccine" for atherosclerosis. | Pre-Seed; raised from Sila B Health Ventures. Netcapital offering closed Jan 2026. | Immunotherapy approach aimed at clearing existing plaques; initial preclinical data in mice. | [Netcapital], [Wixdom] |
| Cleara Biotech | Developing senolytic therapies targeting the FOXO4-p53 interaction. | Private; Series B raised $43M in 2023. | Focus on peptide-based senolytics; multiple preclinical programs. | [Crunchbase, 2023] |
| Unity Biotechnology | Clinical-stage biotech developing senolytic medicines for ophthalmology and neurology. | Public (UBX); ~$100M market cap (April 2025). | Most advanced clinical pipeline in senolytics; lead candidate in Phase 2 for diabetic macular edema. | [Unity Biotech website] |
| Oisín Biotechnologies | Developing a lipid nanoparticle-delivered gene therapy platform for senolytic applications. | Private; non-dilutive and venture funding. | In vivo genetic reprogramming approach; platform applicable across tissues. | [Company website] |
Where Vertical Longevity has a potential edge today is in its specific technical premise and early-stage capital alignment. The VLP-based immunotherapy approach is less common in senolytics than small molecules or peptides, which could offer a different safety and delivery profile. The company's sole disclosed institutional investor, Sila B Health Ventures, is a boutique firm founded in 2024 that explicitly targets early-stage biopharma for aging-related chronic diseases [PitchBook, Retrieved 2026]. This suggests a partner aligned with the long, capital-intensive preclinical path. However, this edge is highly perishable. It hinges entirely on generating compelling primate study data to de-risk the platform before larger, better-funded entities with similar scientific insights decide to enter the space or before direct competitors advance their own programs into cardiovascular indications.
The company's most significant exposure is its stage and resource gap relative to funded peers. Cleara Biotech's $43 million Series B provides a multi-year runway for development [Crunchbase, 2023]. Unity Biotechnology, despite clinical setbacks, retains public market access and a validated clinical development organization. Vertical Longevity's undisclosed pre-seed funding, while sufficient for initial primate studies, leaves it vulnerable to the notorious "valley of death" between preclinical proof-of-concept and an Investigational New Drug (IND) application. Furthermore, the company has not publicly disclosed any intellectual property holdings, such as patent filings covering its VLP construct or target epitopes, which are the primary currency for defensibility in biotech.
The most plausible 18-month competitive scenario involves a race for compelling non-human primate data and partnership discussions. If Vertical Longevity's upcoming primate studies demonstrate clear plaque reduction without significant toxicity, it becomes a credible asset for a partnership with a mid-sized pharma company seeking early-stage cardiovascular innovation. The "winner" in this near-term frame would be the entity that generates the cleanest in vivo data package with a clear path to IND. Conversely, the "loser" would be any preclinical senolytic program that fails to show a meaningful therapeutic effect in a relevant disease model, likely leading to investor attrition and a down-round or shutdown. For Vertical Longevity, the specific risk is that its VLP platform may not achieve the desired cell-type specificity or potency in a complex primate system, a hurdle that has stalled many novel immunotherapy approaches.
Data Accuracy: YELLOW -- Competitor profiles are assembled from public sources and company websites; funding and stage data for competitors is dated. Vertical Longevity's positioning is confirmed by its own materials and a third-party profile.
Opportunity
PUBLIC
If the preclinical data translates to a safe and effective human therapy, Vertical Longevity Pharma is pursuing a single-shot treatment for the world's leading cause of death, a market measured in hundreds of billions of dollars.
The headline opportunity is the establishment of a first-in-class senolytic vaccine as a new standard of care for atherosclerosis, the underlying pathology of cardiovascular disease. The company's preclinical mouse studies, which demonstrated plaque prevention and cardiac function restoration, provide the initial biological rationale for a platform that could move beyond managing symptoms to clearing the cellular cause of arterial plaques [Kingscrowd, 2025]. The focus on a virus-like particle (VLP) approach aims to create a low-cost, targeted immunotherapy, a profile that could address both the massive patient population and the cost pressures of healthcare systems [Netcapital]. This positions the company not as another drug developer but as a potential category-defining platform in the emerging field of senolytic therapeutics.
Plausible paths to scale are not monolithic; they depend on specific clinical and commercial inflection points. The following scenarios outline distinct, evidence-backed trajectories.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Cardiovascular Franchise | The VLP therapy gains FDA approval for atherosclerosis, becoming a foundational treatment used in combination with statins and PCSK9 inhibitors. | Successful completion of IND-enabling studies and initiation of Phase I/II trials, supported by the early funding from Sila B Health Ventures [F6S]. | The company's explicit roadmap includes primate studies as a next step toward clinical trials, indicating a defined regulatory path [Company site]. |
| Platform Expansion | The validated VLP senolytic platform is applied to other age-related conditions like osteoarthritis, pulmonary fibrosis, or neurodegenerative diseases. | Publication of robust, peer-reviewed data demonstrating selective clearance of senescent cells in the initial atherosclerosis model. | The company's own materials state the platform "could expand to other age-related diseases," framing atherosclerosis as the initial indication [Netcapital]. |
Compounding success in this field would likely manifest as a data and expertise moat, not a classic network effect. Each clinical trial, particularly in a complex area like immunology, generates proprietary data on dosing, safety, and biomarker response that informs and de-risks subsequent programs. A successful first indication would provide validation for the entire VLP senolytic approach, attracting partnership interest and reducing the cost of capital for follow-on programs. The early backing from a specialized firm like Sila B Health Ventures, which focuses on aging-related chronic diseases, suggests an initial alignment with investors who understand this long-term, platform-building thesis [PitchBook].
The size of the win can be contextualized by looking at the market it intends to disrupt. Atherosclerotic cardiovascular disease is a primary driver of a global cardiovascular therapeutics market valued at over $100 billion [various analyst reports]. More specific to the technology, the market potential for senolytic therapies is frequently compared to that of major biologic drug classes. While Vertical Longevity is at a preclinical stage, a credible scenario for a successful, approved senolytic vaccine targeting a major indication could support a valuation comparable to other late-stage biotech platforms, which often reach billions of dollars based on the addressable patient population and premium pricing for transformative therapies. This represents a scenario-based outcome, not a forecast.
Data Accuracy: YELLOW -- Opportunity framing relies on company-stated plans and preclinical data; market size references are from common industry reports. The platform expansion claim is cited directly from company materials.
Sources
PUBLIC
[Netcapital] Learn about Vertical Longevity Pharma | https://netcapital.com/companies/vertical-longevity
[Company site] Vertical Longevity Pharma | https://vertical-longevity-pharma.com/
[The Bioinformatics CRO Podcast] David Scieszka - The Bioinformatics CRO Podcast | https://www.bioinformaticscro.com/podcast/david-scieszka/
[Kingscrowd, 2025] Vertical Longevity Pharma on NetCapital 2025 | https://kingscrowd.com/vertical-longevity-pharma-on-netcapital-2025/
[Wixdom] Vertical Longevity Pharma | Wixdom | https://www.wixdom.io/app/offerings/netcapital_vertical_longevity_0
[F6S] Vertical Longevity Pharmaceuticals | F6S | https://www.f6s.com/company/vertical-longevity-pharmaceuticals
[American Heart Association] Cardiovascular Disease Cost Burden Report | https://www.heart.org/
[Longevity.Technology] Longevity Therapeutics Market Analysis | https://www.longevity.technology/
[Nature Aging] Regulatory Pathways for Aging-Related Therapies | https://www.nature.com/nataging/
[Crunchbase, 2023] Cleara Biotech Funding | https://www.crunchbase.com/
[Unity Biotech website] Unity Biotechnology Pipeline | https://www.unitybiotechnology.com/
[PitchBook, Retrieved 2026] Sila B investment portfolio | PitchBook | https://pitchbook.com/profiles/investor/640045-72
Articles about Vertical Longevity Pharma
- A Senolytic Vaccine Aimed at the Arterial Plaque Itself — Vertical Longevity Pharma, an Irvine preclinical biotech, is engineering virus-like particles to clear the senescent cells driving atherosclerosis.